摘要
Multiple organ dysfunction syndrome (MODS) or multiple organ failure ( MOF)is a syndrome which is frequently related to shock and sepsis, and has been described as the mostcommon cause of death in the noncoronary critical care unit. The potential pathogenesis of theseptic and systemic inflammatory response syndrome (SIRS) response has been increasingly associatedwith the development and aggravation of MODS or MOF. And studies in this respect have alsodemonstrated that there is a higher risk of mortality associated with some specific organ systemswhen they are dysfunctional, thus leading to the failures of the liver, brain, lung, and kidney. Theliver interacts with many other organ systems, and liver dysfunction may act collectively in theproduction of organ system dysfunction, thus finally ending up with MODS. The management of patientswith MODS/MOF is predominantly supportive and some specific treatments are directed at treating theunderlying disorders. The molecular adsorbent recirculating system (MARS) is an albumin dialysissystem and it was shown to be efficient in removing both hydrosoluble substances and stronglyalbumin-bound substances, so that it improves not only the function of the liver but also that ofother organ systems, and it can be applied to treating the diseased liver as the cause of multipleorgan failure and actively combat deterioration in patients' liver function. This trial aims atevaluating the therapeutic effectiveness of MARS in 39 various pathogenic MODS patients in ourhospital and Beijing Ditan Hospital.
Multiple organ dysfunction syndrome (MODS) or multiple organ failure ( MOF)is a syndrome which is frequently related to shock and sepsis, and has been described as the mostcommon cause of death in the noncoronary critical care unit. The potential pathogenesis of theseptic and systemic inflammatory response syndrome (SIRS) response has been increasingly associatedwith the development and aggravation of MODS or MOF. And studies in this respect have alsodemonstrated that there is a higher risk of mortality associated with some specific organ systemswhen they are dysfunctional, thus leading to the failures of the liver, brain, lung, and kidney. Theliver interacts with many other organ systems, and liver dysfunction may act collectively in theproduction of organ system dysfunction, thus finally ending up with MODS. The management of patientswith MODS/MOF is predominantly supportive and some specific treatments are directed at treating theunderlying disorders. The molecular adsorbent recirculating system (MARS) is an albumin dialysissystem and it was shown to be efficient in removing both hydrosoluble substances and stronglyalbumin-bound substances, so that it improves not only the function of the liver but also that ofother organ systems, and it can be applied to treating the diseased liver as the cause of multipleorgan failure and actively combat deterioration in patients' liver function. This trial aims atevaluating the therapeutic effectiveness of MARS in 39 various pathogenic MODS patients in ourhospital and Beijing Ditan Hospital.
